Lung cancer hope: drug combo before surgery shows promise
NCT ID NCT05882513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the immunotherapy drug serplulimab together with chemotherapy before surgery can help shrink non-small cell lung cancer and improve outcomes. About 36 adults with stage IIA to IIIB lung cancer will receive the combination, then have surgery to remove the tumor. The goal is to see if this approach leads to no cancer cells left in the removed tissue and reduces the chance of the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China, 310009, China